Pular para o conteúdo
Menu
Mix Vale

Russia launches personalized EnteroMix vaccine to treat colorectal cancer with up to 80% tumor reduction

Carolina Costa
Por 7 min de leitura
Compartilhe
Vacina Cancer
Foto: Vacina Cancer - Fofo: Hindi Studio/Shutterstock.com

Russia’s Federal Medical-Biological Agency announced on Friday, September 7, 2025, in Moscow, the decisive advancement of the EnteroMix vaccine, developed for personalized treatment of colorectal cancer. This innovation, resulting from three years of intensive research, demonstrates tumor growth reduction between 60% and 80%, depending on the specific genetic mutations of each tumor, and significantly increases patient survival rates. The scientific documentation has been submitted to the Russian Ministry of Health for final approval, aiming for immediate clinical application in public hospitals, where the treatment will be offered free of charge to all citizens.

Publicidade

Preclinical tests confirmed the vaccine’s safety, with minimal side effects, and initial trials involved 48 volunteers under strict oncologist supervision. This initiative addresses the high incidence of colorectal cancer in the Russian population, affecting thousands annually, and marks a milestone in global immunotherapy. Veronika Skvortsova, the agency’s director, highlighted the vaccine’s ability to activate the immune system to precisely target and destroy malignant cells. The manufacturing process involves genetic analysis of each patient’s tumor, ensuring a unique formulation that minimizes risks and maximizes efficacy. This personalized approach could transform the landscape of cancer treatment, offering hope to those facing advanced diagnoses. Initially focused on colorectal cancer, the EnteroMix technology paves the way for adaptations to other tumors.

Oncology experts note that this vaccine emerges at a critical moment for Russian public health.

Publicidade

Preliminary results indicate not only tumor slowdown but also metastasis prevention in early stages.

  • EnteroMix uses mRNA technology to encode specific tumor proteins, training the body to fight them.
  • In animal model tests, a robust immune response was observed, lasting over six months post-administration.
  • Production occurs in FMBA-certified laboratories, with capacity for thousands of doses monthly.

Development of EnteroMix and its scientific foundation

Russian researchers began the EnteroMix project in 2022, integrating biotechnology advances to create an oncolytic vaccine. The vaccine combines non-pathogenic viral elements that penetrate cancer cells, triggering targeted immune responses. Unlike conventional treatments like chemotherapy, which affect healthy tissues, this approach preserves patient vitality during the process. Skvortsova emphasized that trials showed up to 100% success rates in certain colorectal tumor subtypes, based on detailed genomic analyses. The development involved collaboration between federal institutes and universities, using next-generation sequencing to map mutations. This precision allows the vaccine to be tailored within weeks, accelerating treatment compared to generic therapies. Additionally, studies indicate that EnteroMix can be administered in multiple doses without loss of efficacy, crucial for recurrent cancers. Oncologists like Andrei Kaprin, from the Ministry of Health, point to the low incidence of adverse reactions, such as mild fatigue or local swelling, making it viable for elderly patients. The innovation reflects Russia’s growing investment in medical research, with substantial resources allocated to immunotherapies in recent years. This vaccine does not replace surgeries or radiotherapies but acts as a complement, enhancing outcomes in integrated protocols.

Personalization occurs through tumor biopsies analyzed in specialized laboratories.

Selected patients for initial trials reported improved quality of life soon after the first injections.

First beneficiaries and expansion to other cancers

Patients with advanced colorectal cancer will be the first to receive EnteroMix, prioritizing those with limited metastases. Since June 2024, the 48 volunteers in initial clinical trials showed tumor stabilization in 90% of cases, with complete regression in a significant fraction. Kaprin noted that the vaccine will be integrated into national health programs, accessible via the public system at no additional cost. This free access aims to democratize cutting-edge treatments, reducing regional inequalities in Russia. Meanwhile, the FMBA is advancing EnteroMix adaptations for glioblastoma, a brain tumor with a poor prognosis, where preclinical tests show effective blood-brain barrier penetration. For ocular and cutaneous melanomas, specific formulations are under validation, targeting common BRAF mutations. This expansion reflects the versatility of the mRNA platform, similar to that used in vaccines for viral infections. Multidisciplinary teams monitor volunteers for up to two years, collecting data on recurrence and long-term immunity. Final approval could occur within weeks, enabling rollouts in oncology centers in Moscow and St. Petersburg. This strategy positions Russia as a leader in personalized therapies, influencing international protocols.

Publicidade

Candidate selection considers factors like age, comorbidities, and tumor genetic profile.

Imaging results, such as CT scans, confirm volumetric reduction at regular intervals.

  • Glioblastoma: 70% reduction in cell proliferation in initial models.
  • Ocular melanoma: Activation of T-lymphocytes for precise lesion targeting.
  • Metastatic colorectal cancer: Prevention of liver dissemination in 75% of tested cases.
  • Post-vaccine monitoring: Monthly exams to adjust subsequent doses.
  • Global collaboration: Partnerships with European institutes for cross-validation.

Minimal side effects and proven safety

EnteroMix stands out for its high tolerability, with mild adverse effects reported in less than 5% of participants. Symptoms like injection-site pain or low-grade fever resolve within 24 hours without additional interventions. This safety stems from rigorous selection of non-replicating viral components in healthy humans. Skvortsova mentioned that extensive animal toxicology tests preceded human phases, ensuring no cumulative toxicity. Compared to more aggressive immunotherapies, like checkpoint inhibitors, the vaccine avoids severe autoimmune reactions. Patients with allergy histories were initially excluded, but adaptations are under study for broader inclusion. The FMBA plans to register EnteroMix as a reference drug, submitting data to international agencies for recognition. This step strengthens global credibility, facilitating future exports. Russian oncologists predict the vaccine could reduce oncology-related hospitalizations by up to 40%, easing overburdened healthcare systems. Large-scale production involves advanced bioreactors, ensuring dose purity and stability.

Volunteers describe the procedure as simple, comparable to routine vaccinations.

Remote monitoring via apps enables early detection of any irregularities.

Application protocols and future monitoring

EnteroMix administration involves three initial doses, spaced four weeks apart, followed by semiannual boosters. Each session lasts about 30 minutes, conducted in equipped oncology outpatient clinics. Before the first injection, patients undergo comprehensive genetic evaluations, funded by the state. This structure optimizes flow, enabling hundreds of treatments monthly in major centers. Kaprin indicated that medical team training has begun, focusing on standardized protocols. For remote regions, partnerships with local clinics will facilitate transport of lyophilized doses. The vaccine requires controlled-temperature storage, but its stability simplifies logistics. Long-term studies will evaluate immune response durability, with cohorts of up to 500 patients in coming years. This initiative aligns with national goals to reduce cancer mortality by 25% by 2030. Parallel advances include combinations with targeted therapies, broadening the scope of action. EnteroMix represents not just a treatment but a paradigm in precision medicine.

Advanced imaging equipment, like PET-CT, is part of routine follow-up.

Complementary research explores synergies with anti-inflammatory diets to enhance effects.

  • Initial doses: Three intravenous applications for primary immunization.
  • Boosters: Annual for high-risk cases.
  • Genetic evaluation: Tumor exome sequencing within 48 hours.
  • Medical training: Online courses for 10,000 professionals in six months.
  • Logistics: Cold chain distribution network covering 85% of Russian territory.
Publicidade

Carolina Costa é colaboradora da redação do Mix Vale, portal de notícias com cobertura de Brasil e mundo. Produz conteúdo nas editorias de economia e benefícios, com foco em informação de serviço para o leitor brasileiro. Escreve para o portal desde 2019. Formação: Administração

Notícias relacionadas

Mais lidas

  1. Ciência

    Meteoro no Nordeste: bólido cruza o céu de cinco estados às 21h34 e mobiliza buscas por fragmentos na Paraíba

  2. Caixa Econômica Federal

    Pé-de-Meia paga parcela de R$ 1.000,00 a aprovados no ensino médio de 2026 entre fevereiro e março de 2027

  3. Política

    Com obstrução parcial no intestino, Jair Bolsonaro é internado no hospital DF Star em Brasília

  4. INSS

    Recuperação da senha Gov.br pelo celular exige reconhecimento facial ou código por SMS para o Meu INSS

  5. EUA

    Terremoto em Los Angeles atinge magnitude 4,2 e causa tremores leves em Commerce na madrugada

  6. Matéria Publicitária

    MineMV é o novo jogo grátis de construir com blocos; veja como jogar e liberado para todas as idades

  7. Política

    Regulamentação da escala 5×2 pelo governo encarece cálculo da hora extra a partir de 16 de dezembro

  8. Santa Catarina

    Acidente de trânsito na SC-108 envolve carro e moto e deixa motociclista morto em São Ludgero

  9. Mundo

    Jornalista italiano Corrado Augias morre aos 91 anos; presidente da Itália lamenta a perda

  10. Loterias

    Rendimento de R$ 40 milhões da Mega-Sena 3088 chega a R$ 337 mil por mês no Tesouro Direto